Literature DB >> 21920026

Dissociation of blood pressure and resistance artery structure: potential clinical implications.

Kent L Christensen1, Niels H Buus.   

Abstract

Essential hypertension (EH) is associated with structural changes in small arteries (SMASCH) in terms of wall thickening and lumen narrowing throughout the entire resistance circulation. This remodelling process occurs early in EH development and is an important contributor to the elevation of vascular resistance. SMASCH also decreases the vasodilatory capability leading to demand-related organ dysfunction (e.g. microvascular angina) and later contributes to organ failure as seen in hypertensive heart and renal failure. In large groups of patients, office blood pressure (BP) precisely predicts strokes and myocardial infarctions, but it is difficult to apply risk prediction equations based on studies of large numbers of patients in individual patients. Office BP may be a rather poor predictor of future cardiovascular events. Adding other risk factors unrelated to BP (SCORE factors) improves risk prediction, and in subgroups with intermediate risk, there may be added value of considering BP-related parameters such as albuminuria or left ventricular hypertrophy. Being directly related to the process of hyper-resistance and dissociated from BP itself, measurements of SMASCH may contribute to risk over and above office BP and other traditional risk parameters. Furthermore, as only antihypertensive treatment regimens resulting in vasodilatation seem to improve SMASCH, this parameter has the potential to guide and improve the management of EH. SMASCH can be assessed, for example, by plethysmography in the forearm or by echocardiography in the heart. These techniques are accurate and reproducible and could constitute part of the diagnostic apparatus for EH patients. This review focuses on methodological issues of SMASCH, haemodynamic consequences, implementation in the clinical setting and suggestions for future research.
© 2011 The Authors. Basic & Clinical Pharmacology & Toxicology © 2011 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920026     DOI: 10.1111/j.1742-7843.2011.00799.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  3 in total

1.  Positive effects of aggressive vasodilator treatment of well-treated essential hypertensive patients.

Authors:  M Engholm; M J Mulvany; A Eftekhari; O N Mathiassen; N H Buus; K L Christensen
Journal:  J Hum Hypertens       Date:  2016-03-10       Impact factor: 3.012

2.  Self-Monitoring Home Blood Pressure in Community-Dwelling Older People: Age Differences in White-Coat and Masked Phenomena and Related Factors-The SONIC Study.

Authors:  Jinmei Tuo; Kayo Godai; Mai Kabayama; Yuya Akagi; Hiroshi Akasaka; Yoichi Takami; Yasushi Takeya; Koichi Yamamoto; Ken Sugimoto; Saori Yasumoto; Yukie Masui; Yasumichi Arai; Kazunori Ikebe; Yasuyuki Gondo; Tatsuro Ishizaki; Hiromi Rakugi; Kei Kamide
Journal:  Int J Hypertens       Date:  2022-04-30       Impact factor: 2.434

3.  Cardiac magnetic resonance assessment of central and peripheral vascular function in patients undergoing renal sympathetic denervation as predictor for blood pressure response.

Authors:  Karl Fengler; Karl-Philipp Rommel; Stephan Blazek; Maximilian Von Roeder; Christian Besler; Christian Lücke; Matthias Gutberlet; Jennifer Steeden; Michael Quail; Steffen Desch; Holger Thiele; Vivek Muthurangu; Philipp Lurz
Journal:  Clin Res Cardiol       Date:  2018-05-09       Impact factor: 5.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.